VEGFR1-14/Flt1-14, soluble Human 20 µg

In stock

Cat-Nr.
S01-072
Size
20 µg
  €268.00

Description / VEGFR1-14/Flt1-14, soluble

A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in non-endothelial cells. Notably, in vascular smooth muscle cells, all Flt1 messenger RNA is converted to sFlt1-14, whereas endothelial cells of the same human vessel express sFlt1. sFlt1-14 expression by vascular smooth muscle cells is dynamically regulated as evidenced by its upregulation on coculture with endothelial cells or by direct exposure to VEGF. Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester. Expression is dramatically elevated in the placenta of women with preeclampsia, specifically induced in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots, where it may undergo further messenger RNA editing. sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclamptic placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. Together, these findings revealed a new natural VEGF inhibitor that has evolved in humans, possibly to protect non-endothelial cells from adverse VEGF signaling. Furthermore, the study uncovered the identity of a VEGF-blocking protein implicated in preeclampsia.

More Information

Size 20 µg
Source Insect cells
Biological Activity The activity of sFlt1-14 was determined by its ability to inhibit the VEGF-A-induced proliferation of HDLECs.
N Terminal Sequence SKLKD
Purity Confirmation > 95% by SDS-PAGE & visualized by Coomassie stain
Length [aa] 707
Molecular Weight 105. kDa
Species Reactivity Human
Formulation lyophilized
Buffer PBS
Protein Sequence SKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRR
Reconstitution The lyophilized sFlt1-14 is soluble in water and most aqueous buffers. The lyophilized sFlt1-14 should be reconstituted in water to a concentration not lower than 100µg/ml.
Stability and Storage Lyophilized samples are stable for greater than six months at -20°C to -70°C. Reconstituted sFlt1-14 should be stored in working aliquots at -70°C. Avoid repeated freeze-thaw cycles!
Synonyms soluble vascular endothelial growth factor receptor-1; soluble FLT1; soluble VEGFR-1, sFlt1-14
Uniprot ID P17948-3
Protein RefSeq NP_001153502.1
mRNA RefSeq NM_001160030.1

Compatible products

Navigating through the elements of the carousel is possible using the tab key. You can skip the carousel or go straight to carousel navigation using the skip links.
SKU: 101-M29
€275.00

In stock

All prices plus VAT + possible delivery charges